Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Outlook Therapeutics (NASDAQ:OTLK) issued its earnings results on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Price Performance

Shares of NASDAQ OTLK traded up $0.09 during mid-day trading on Friday, hitting $1.93. The company’s stock had a trading volume of 437,190 shares, compared to its average volume of 868,180. The stock has a market cap of $61.56 million, a price-to-earnings ratio of -0.22 and a beta of 0.58. The company’s fifty day simple moving average is $1.86 and its 200-day simple moving average is $4.56. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85.

Analysts Set New Price Targets

Several research firms have recently weighed in on OTLK. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research dropped their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.40.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.